WallStreetZenWallStreetZen

NASDAQ: CAPR
Capricor Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CAPR

Based on 3 analysts offering 12 month price targets for Capricor Therapeutics Inc

Min Forecast
$21.00+229.15%
Avg Forecast
$24.67+286.63%
Max Forecast
$28.00+338.87%

Should I buy or sell CAPR stock?

Based on 5 analysts offering ratings for Capricor Therapeutics Inc.

Buy
Strong Buy
3 analysts 60%
Buy
0 analysts 0%
Hold
2 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CAPR's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CAPR as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their CAPR stock forecasts and price targets.

CAPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-14
lockedlocked$00.00+00.00%2026-09-01
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-07-31
lockedlocked$00.00+00.00%2026-07-30

1 of 1

Forecast return on equity

Is CAPR forecast to generate an efficient return?

Company
103.08%
Industry
21.4%
Market
176.67%
CAPR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CAPR forecast to generate an efficient return on assets?

Company
68.83%
Industry
21.92%
CAPR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CAPR earnings per share forecast

What is CAPR's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$2.29
Avg 2 year Forecast
-$1.76
Avg 3 year Forecast
-$0.72

CAPR revenue forecast

What is CAPR's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$50.1M
Avg 2 year Forecast
$39.6M
Avg 3 year Forecast
$180.4M

CAPR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CAPR$6.38$24.67+286.63%Buy
AGMB$7.49$43.00+474.10%Strong Buy
RLMD$3.58$12.00+235.20%Buy
RZLT$3.95$10.13+156.33%Strong Buy
FENC$10.24$16.67+62.76%Strong Buy
View Top Biotech Stocks

Capricor Therapeutics Stock Forecast FAQ

Is Capricor Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CAPR) stock is to Buy CAPR stock.

Out of 5 analysts, 3 (60%) are recommending CAPR as a Strong Buy, 0 (0%) are recommending CAPR as a Buy, 2 (40%) are recommending CAPR as a Hold, 0 (0%) are recommending CAPR as a Sell, and 0 (0%) are recommending CAPR as a Strong Sell.

If you're new to stock investing, here's how to buy Capricor Therapeutics stock.

What is CAPR's earnings growth forecast for 2026-2028?

(NASDAQ: CAPR) Capricor Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.55%.

Capricor Therapeutics's earnings in 2026 is -$129,416,560.On average, 12 Wall Street analysts forecast CAPR's earnings for 2026 to be -$132,911,543, with the lowest CAPR earnings forecast at -$156,684,575, and the highest CAPR earnings forecast at -$65,319,154. On average, 11 Wall Street analysts forecast CAPR's earnings for 2027 to be -$102,219,970, with the lowest CAPR earnings forecast at -$161,812,434, and the highest CAPR earnings forecast at -$6,715,053.

In 2028, CAPR is forecast to generate -$41,958,908 in earnings, with the lowest earnings forecast at -$129,335,995 and the highest earnings forecast at $56,772,723.

What is CAPR's revenue growth forecast for 2026-2028?

(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.67%.

Capricor Therapeutics's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast CAPR's revenue for 2026 to be $2,910,670,345, with the lowest CAPR revenue forecast at $0, and the highest CAPR revenue forecast at $12,941,738,951. On average, 11 Wall Street analysts forecast CAPR's revenue for 2027 to be $2,299,862,127, with the lowest CAPR revenue forecast at $255,927,830, and the highest CAPR revenue forecast at $4,670,014,291.

In 2028, CAPR is forecast to generate $10,487,110,836 in revenue, with the lowest revenue forecast at $3,844,673,204 and the highest revenue forecast at $23,997,449,100.

What is CAPR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CAPR) forecast ROA is 68.83%, which is higher than the forecast US Biotechnology industry average of 21.92%.

What is CAPR's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CAPR price target, the average CAPR price target is $24.67, with the highest CAPR stock price forecast at $28.00 and the lowest CAPR stock price forecast at $21.00.

On average, Wall Street analysts predict that Capricor Therapeutics's share price could reach $24.67 by Sep 14, 2027. The average Capricor Therapeutics stock price prediction forecasts a potential upside of 286.63% from the current CAPR share price of $6.38.

What is CAPR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CAPR) Capricor Therapeutics's current Earnings Per Share (EPS) is -$2.45. On average, analysts forecast that CAPR's EPS will be -$2.29 for 2026, with the lowest EPS forecast at -$2.70, and the highest EPS forecast at -$1.12. On average, analysts forecast that CAPR's EPS will be -$1.76 for 2027, with the lowest EPS forecast at -$2.78, and the highest EPS forecast at -$0.12. In 2028, CAPR's EPS is forecast to hit -$0.72 (min: -$2.22, max: $0.98).

What is CAPR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CAPR) forecast ROE is 103.08%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.